Skip to main content

Table 4 Adverse events (any grade) with an incidence of ≥20%, safety population

From: Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results

Adverse event Cohort 1: pertuzumab, trastuzumab, and vinorelbine N = 106
Any adverse event 105 (99.1%)
 Diarrhea 61 (57.5%)
 Neutropenia 54 (50.9%)
 Nausea 52 (49.1%)
 Asthenia 42 (39.6%)
 Pyrexia 37 (34.9%)
 Anemia 36 (34.0%)
 Fatigue 36 (34.0%)
 Constipation 35 (33.0%)
 Vomiting 34 (32.1%)
 Chills 30 (28.3%)
 Alopecia 27 (25.5%)
 Rash 25 (23.6%)
 Leukopenia 24 (22.6%)
 Decreased appetite 23 (21.7%)
 Weight decreased 22 (20.8%)
  1. Data are reported number (%)